Advanced searches left 3/3

Influenza Vaccine - PubAg

Summarized by Plex Scholar
Last Updated: 16 October 2021

* If you want to update the article please login/register

Introductory paper: High-dose influenza vaccine

Seasonal influenza has a considerable impact on global public health each year, particularly in older adults 65 years of age and over. The growth of the high-dose influenza vaccine stands for an essential action in the advancement of influenza vaccines, offering an advancement in prevention of influenza and an action in motivating healthy aging in older grownups.

Source link: https://pubag.nal.usda.gov/catalog/7266412


A validated modification of the vaccine hesitancy scale for childhood, influenza and HPV vaccines

We after that made use of confirmatory and exploratory factor analysis to create and identify hidden constructs customized ranges for hpv, youth and influenza vaccines with boosted psychometric properties. Hesitancy was strongly linked with vaccine receipt: e. g. , 76% of parents not reluctant in the direction of influenza vaccine had vaccinated their youngster the previous period, versus 9% of hesitant parents. Subscale ratings additionally differed significantly in between vaccines: uncertainty was higher in the direction of influenza and HPV vaccines than childhood years vaccines; viewed risks of HPV vaccines were higher than for youth vaccines. Our modified VHS ranges execute well psychometrically and permit regular dimension of the level and factors for hesitancy between vaccine categories.

Source link: https://pubag.nal.usda.gov/catalog/7300560


Comparison of local influenza vaccine effectiveness using two methods

In some settings, research approaches to establish influenza vaccine efficiency may not be suitable due to the fact that of cost, time restrictions, or various other variables. Odds ratios for chance of influenza infection by vaccination condition were computed using multivariable logistic regression. VE was substantial versus all influenza and influenza A in each season and both periods incorporated 37-- 49%. When registration sites were independently examined, there were substantial differences in VE estimates for all influenza 66% research study vs. 46% management P < 0. 001 and influenza A 67% research vs. 49% management; P < 0. 001 in the emergency department. The option of the appropriate approach for determining influenza vaccine efficiency depends on many aspects, consisting of example dimension, subgroups of rate of interest, and so on, suggesting that research estimates might be much more generalizable.

Source link: https://pubag.nal.usda.gov/catalog/7253869


In silico prediction of influenza vaccine effectiveness by sequence analysis

The efficiency of seasonal influenza vaccines differs with the matching of vaccine stress to circulating stress. Based on the hereditary range of hemagglutinin and neuraminidase gene of the influenza viruses to vaccine strains, we statistically quantified the relationship in between the genetic mismatch and vaccine performance for influenza B, a/h3n2 and a/h1n1pdm09.

Source link: https://pubag.nal.usda.gov/catalog/7241909


Global production capacity of seasonal and pandemic influenza vaccines in 2019

While research study in the direction of establishing universal influenza vaccines is continuous, the current approach for vaccine supply in a pandemic depends on seasonal influenza vaccine manufacturing to be switched to pandemic vaccines. Through the Global Action Plan for Influenza Vaccines, 2006-- 2016, WHO advertised an increase in vaccine production capacity and keeps an eye on the landscape via regularly surveying influenza vaccine suppliers. This research compares worldwide ability for production of influenza vaccines in 2019 with estimates from previous surveys; offers an introduction of countries with well-known production facilities; offers vaccine manufacturing by type and production procedure; and discusses limitations to these estimates. Outcomes of the present survey reveal that approximated yearly seasonal influenza vaccine production capability changed little since 2015 increasing from 1. 47 billion to 1. 48 billion dosages with prospective optimal yearly influenza pandemic vaccine manufacturing capability raising from 6. 37 billion to 8. 31 billion doses.

Source link: https://pubag.nal.usda.gov/catalog/7209207


Reports of cell-based influenza vaccine administered during pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2013–2020

In November 2012, the first cell cultured influenza vaccine, a trivalent subunit inactivated influenza vaccine, was approved in the United States for adults aged ≥ 18 years. The safety and security of ccIIV3 or ccIIV4 was not examined for pregnant females or their infants throughout pre-licensure studies. To examine the safety of ccIIV provided while pregnant in expecting women and their infants whose reports were submitted to VAERS during 2013-- 2020. We browsed VAERS for United States records of negative events in expectant females that obtained ccIIV from 1 July 2013 with 31 May 2020. Fifteen birth issues were reported; in 12 with gestational age information, administration of the vaccine occurred late in the second trimester or later. Review of maternal ccIIV reports in VAERS was not suddenly different from other maternal influenza vaccine safety VAERS reviews.

Source link: https://pubag.nal.usda.gov/catalog/7219139


Older adults' vaccine hesitancy: Psychosocial factors associated with influenza, pneumococcal, and shingles vaccine uptake

Participants were in addition offered the opportunity to supply free text responses describing as much as three major factors for their vaccination choices. We discovered that substantially even more participants had received the influenza vaccine in the last 12 months, relative to having ever got the pneumococcal and roof shingles vaccines. Participants were more familiar with their qualification for the influenza vaccine, and were much more likely to have been provided it. Multivariate logistic regression evaluations revealed that a lower sense of collective duty separately predicted lack of uptake of all 3 vaccines. Greater calculation of condition and vaccination danger, and preference for natural immunity, additionally anticipated not getting the influenza vaccine. Our findings recommend that interventions targeted towards older grownups would benefit from being vaccine-specific and that they ought to stress illness dangers and vaccine advantages for the person, along with the advantages of vaccination for the broader community.

Source link: https://pubag.nal.usda.gov/catalog/7385416


Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: Reports to the vaccine adverse event reporting system

On October 7, 2016, the Food and Drug Administration approved recombinant hemagglutinin quadrivalent influenza vaccine for active booster shot for the prevention of influenza illness in individuals 18 years of age and older. Medical tests did not reveal any kind of major distinctions in adverse occasions or serious damaging events adhering to Flublok Quadrivalent versus standard-dose quadrivalent suspended influenza vaccine. To enhance our understanding of the safety and security profile of this vaccine, we evaluated and summarized damaging occasion reports after Flublok Quadrivalent administration to the Vaccine Adverse Event Reporting System. The incident of anaphylaxis and other allergies in some people may show a hidden tendency to atopy that may materialize itself after an exposure to any type of medicine or vaccine, and does not always recommend that Flublok Quadrivalent is especially allergenic. Postmarketing security monitoring will continue to be vital for comprehending the benefits and risks of quadrivalent recombinant influenza vaccine.

Source link: https://pubag.nal.usda.gov/catalog/7304918


Bat influenza vectored NS1-truncated live vaccine protects pigs against heterologous virus challenge

Swine influenza is an important condition for the swine market. When the vaccine strains inequality with the infected infections, currently utilized whole inactivated infection vaccines can induce vaccine-associated boosted respiratory illness in pigs. Live attenuated influenza virus vaccine is effective to safeguard pigs versus heterologous and homologous swine influenza virus infections without generating VAERD but has safety and security worries as a result of potential reassortment with flowing infections. 2 attenuated MLV vaccine prospects consisting of the infection that reveals an abbreviated NS1 or expresses both an abbreviated NS1 and the swine IL-18 were created and reviewed in pigs versus a heterologous H3N2 virus using the WIV vaccine as a control. These results show that bat influenza vectored MLV vaccines can be used as a safe live vaccine to stop swine influenza.

Source link: https://pubag.nal.usda.gov/catalog/7317045

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions